Delivery Order SPE2DB22D3010-SPE2DB25FP2AK

Award Date 3/26/25
Potential Completion Date 3/27/25
Potential Value $1.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,043.63 firm-fixed-price delivery order is for the supply of Olmesartan Medoxomil 40 mg tablets to support military healthcare programs. The award is associated with a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,003.91 firm fixed-price delivery order is for the supply of Olmesartan Medoxomil 40 mg tablets, a cardiovascular medication. The contract has an ultimate completion date of March 24, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,756.35 firm-fixed-price delivery order covers the supply of Olmesartan Medoxomil 40 mg tablets. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,153.15, is a Firm Fixed Price Delivery Order for the supply of Olmesartan Medoxomil 40 mg tablets. The award has an ultimate completion date of November 27, 2024. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
This federal contract award, with ID SPE2DX15D3020|SPE2DX24FXQUK, was granted by the Defense Logistics Agency (DLA) Troop Support Medical division to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $7,120.23 delivery order contract is for the supply of Olmesartan Medoxomil 40 mg tablets. The contract is a firm fixed-price agreement that runs through July 3, 2024. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,453.89 fixed-price delivery order is for the supply of 4,562,817,379 units of the drug Olmesartan Medoxomil 40 mg tablets, with a completion date of November 15, 2023. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Olmesartan Medoxomil 40 mg tablets. The contract, valued at $3,391.38, is a firm fixed-price delivery order with a period of performance ending on September 5, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing...
This federal contract award, valued at $9,745.26, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Olmesartan Medoxomil 40 mg tablets, a medication used to treat high blood pressure. This contract is a delivery order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,580.43 fixed-price delivery order is for the supply of 90 tablets of Olmesartan Medoxomil 40 mg, a cardiovascular medication. The contract has an ultimate completion date of July 12, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award is for the supply of Olmesartan Medoxomil 40 mg tablets to the Defense Logistics Agency (DLA). The $1,068.67 fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on February 6, 2024, with a completion date of February 7, 2024. This award is under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC...
  • SPE2DB22D3010
    Indefinite Delivery Contract
  • SPE2DB22D3010-SPE2DB25FP2AK
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,730.19, is a delivery order for the supply of Olmesartan Medoxomil 40 mg tablets. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has a period of performance through March 2025 and does not have a set-aside designation, indicating open competition.

Generated 6/29/25, 1:11 AM